Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1144-1154

  Ewald, Florian ^a   Nörz, Dominik ^a   Grottke, Astrid ^a   Hofmann, Bianca T ^a   Nashan, Björn ^a   Jücker, Manfred ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AKT; Cholangiocarcinoma; Combinatorial treatment; MEK; mTOR

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 8055; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; SELUMETINIB; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; FUSED HETEROCYCLIC RINGS; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGIOCARCINOMA CELL LINE; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BILE DUCT TUMOR; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; INTRAHEPATIC BILE DUCT; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84927553942     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0149-7     Document Type: Article

References (46)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366(9493):1303-1314. doi: 10.1016/S0140-6736(05)67530-7
2. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98(12):873-875. doi: 10.1093/jnci/djj234
3. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507-517, discussion 517-509
4. Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24(2):189-199. doi: 10.1055/s-2004-828895
5. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41(5):808-814. doi: 10.1016/j.jhep.2004.07.016
6. Wang C, Maass T, Krupp M, Thieringer F, Strand S, Worns MA, Barreiros AP, Galle PR, Teufel A (2009) A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 50(6):1122-1131. doi: 10.1016/j.jhep.2009.01.024
7. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA (2007) AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13(48):6470-6477
8. Hezel AF, Deshpande V, Zhu AX (2010) Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28(21):3531-3540. doi: 10.1200/JCO.2009.27.4787
9. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263-1284. doi: 10.1016/j.bbamcr.2006.10.001
10. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209-2219. doi: 10.1158/1535-7163.MCT-07-0231
11. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29(17):2357-2363. doi: 10.1200/JCO.2010.33.9473
12. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293. doi: 10.1016/j.cell.2012.03.017
13. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550-562. doi: 10.1038/nrc2664
14. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956-1967. doi: 10.1158/1535-7163.MCT-09-1012
15. Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37(1):19-24. doi: 10.1038/ng1494
16. Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29(26):3733-3744. doi: 10.1038/onc.2010.139
17. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, Asara JM, Manning BD, Blenis J, Su B, Wei W (2013) Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol 15(11):1340-1350. doi: 10.1038/ncb2860
18. Wang Z, Zheng T, Wu Q, Wang J, Wu C (2012) Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. Neoplasma 59(2):137-141
19. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM (2009) The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15(2):660-667. doi: 10.1158/1078-0432.CCR-08-1084
20. Markman B, Dienstmann R, Tabernero J (2010) Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 1 (7):530-543. doi:101012 [pii]
21. Lv X, Ma X, Hu Y (2013) Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. Expert Opin Drug Discov. doi: 10.1517/17460441.2013.800479
22. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1(3):248-259. doi: 10.1158/2159-8290.CD-11-0085
23. Pal SK, Reckamp K, Yu H, Figlin RA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19(11):1355-1366. doi: 10.1517/13543784.2010.520701
24. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36(6):320-328. doi: 10.1016/j.tibs.2011.03.006
25. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA (2010) Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124. doi: 10.1371/journal.pone.0014124
26. Scherdin G, Garbrecht M, Klouche M (1987) In vitro interaction of á-difluoromethylornithine (DFMO) and human recombinant interferon-α (rIFN-α) on human cancer cell lines. Immunobiology 175(1-2):1-143
27. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S (1995) Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177(1):61-71
28. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Buschenfelde KH M z (1985) Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1(6):579-596
29. Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jucker M Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal 23 (12):1952-1960. doi:S0898-6568 (11) 00200-2 [pii] 10.1016/j.cellsig.2011.07.003
30. Ewald F, Grabinski N, Grottke A, Windhorst S, Norz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jucker M (2013) Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. doi: 10.1002/ijc.28214
31. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
32. Kandil E, Tsumagari K, Ma J, Abd Elmageed ZY, Li X, Slakey D, Mondal D, Abdel-Mageed AB (2013) Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J Surg Res 184 (2):898-906. doi:S0022-4804 (13) 00246-1 [pii] 10.1016/j.jss.2013.03.052
33. Liao Y, Hung MC (2010) Physiological regulation of Akt activity and stability. Am J Transl Res 2(1):19-42
34. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Bluthgen N (2011) Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol 7:489. doi:msb201127 [pii] 10.1038/msb.2011.27
35. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, Winkler S, Houben P, Schultze D, Hatano E, Schemmer P (2013) Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med 2(6):862-871. doi: 10.1002/cam4.150
36. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-1356. doi: 10.1038/nm.1890
37. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jucker M (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11:85. doi:1476-4598-11-85 [pii] 10.1186/1476-4598-11-85
38. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA (2010) Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 5(9):e13026. doi: 10.1371/journal.pone.0013026
39. Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle R, Johnson LD, Raynaud FI, Selfe J, Thway K, Pietsch T, Pearson AD, Shipley J (2013) Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-0850
40. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK (2012) Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7 (7):e40439. doi: 10.1371/journal.pone.0040439 PONE-D-12-04817 [pii]
41. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (5712):1098-1101. doi:307/5712/1098 [pii] 10.1126/science.1106148
42. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 4 (166):ra17. doi:4/166/ra17 [pii] 10.1126/scisignal.2001752
43. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3 (149):ra84. doi:3/149/ra84 [pii] 10.1126/scisignal.2001148
44. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6 (12):e28973. doi:10.1371/journal.pone.0028973 PONE-D-11-08524 [pii]
45. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72(13):3228-3237. doi: 10.1158/0008-5472.CAN-11-3747
46. Meng J, Peng H, Dai B, Guo W, Wang L, Ji L, Minna JD, Chresta CM, Smith PD, Fang B, Roth JA (2009) High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8(21):2073-2080